Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares gapped down prior to trading on Thursday . The stock had previously closed at $8.33, but opened at $7.84. Gyre Therapeutics shares last traded at $7.86, with a volume of 114,918 shares changing hands.

Wall Street Analysts Forecast Growth

GYRE has been the subject of a number of research analyst reports. Wall Street Zen lowered Gyre Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Gyre Therapeutics presently has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Down 3.2%

The firm has a market capitalization of $727.29 million, a price-to-earnings ratio of 755.76 and a beta of 1.97. The business has a 50-day moving average of $7.96 and a two-hundred day moving average of $7.78.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Barclays PLC lifted its position in Gyre Therapeutics by 38.3% in the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after purchasing an additional 5,135 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Gyre Therapeutics by 37.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after buying an additional 45,772 shares during the period. State Street Corp increased its holdings in Gyre Therapeutics by 10.7% in the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after buying an additional 19,472 shares during the period. Wells Fargo & Company MN raised its stake in shares of Gyre Therapeutics by 132.4% in the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after buying an additional 7,361 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Gyre Therapeutics in the 4th quarter valued at $77,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.